RESEARCH MONOGRAPH · KDC-MN-100

Quercetin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Plain-language summary Intrigue 62 / 100

Quercetin is a natural flavonoid found in onions, apples, and capers. It is one half of the dasatinib-quercetin (D+Q) senolytic combination. Quercetin alone has anti-allergic and anti-inflammatory effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Flavonoid senolytic / mast cell stabilizer

A widely distributed flavonoid with weaker senolytic activity than fisetin, often combined with dasatinib in the canonical D+Q senolytic regimen.

Abstract

Quercetin (3,3',4',5,7-pentahydroxyflavone; CAS 117-39-5; molecular formula C15H10O7; molecular weight 302.24) is a widely distributed flavonoid present in onions, apples, capers, and many other plants. The compound has multiple mechanisms of pharmacological interest: mast cell stabilization (anti-allergic effects), direct antioxidant activity, anti-inflammatory effects through NF-kB inhibition, and senolytic activity (in combination with the kinase inhibitor dasatinib in the canonical D+Q regimen developed by Kirkland and Niedernhofer). The senolytic activity of quercetin alone is modest; the dasatinib combination is substantially more effective. Bioavailability is poor as the free aglycone but better as the rutinose glycoside; plasma quercetin concentrations after oral exposure are typically less than 1 percent of the administered amount. Reported research dose ranges in the literature span roughly 500 mg to 2 grams; the senolytic D+Q regimen described in the literature uses pulsatile windows of 1000 to 1500 mg quercetin with 100 mg dasatinib concentrated over 2 to 3 day periods.

Mechanism of action

Mast cell stabilizer, anti-inflammatory, weak senolytic. The dasatinib + quercetin (D+Q) combination is the established senolytic regimen.

Reported research dose ranges

500 to 2000 mg; 1000-1500 mg in pulsatile D+Q senolytic research protocols (reported research dose ranges in the literature).

References

  1. Zhu Y, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-100

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.